Dr Reddy’s Laboratories Ltd today announced that it has launched Ezetimibe and Simvastatin Tablets in the US market following approval from the US Food and Drug Administration. According to a statement issued by the company, the drug is a therapeutic equivalent generic version of Vytorin (Ezetimibe and Simvastatin) Tablets and Dr Reddy’s is among the first companies to launch the generic product in the US market. The Vytorin brand had US sales of approximately $ 678 million MAT (Moving Annual Total) for the most recent twelve months ended in February 2017 according to IMS Health.
Dr Reddy’s Ezetimibe and Simvastatin Tablets of 10 mg/10 mg, 10 mg/20mg, 10 mg/40 mg, and 10 mg/80 mg, are available in bottle count sizes of 30, 90 and 1000. Vytorin which is indicated for use along with a healthy diet to reduce elevated LDL cholesterol in patients with hyperlipidemia is registered trademark of MSD International GMBH. Dr Reddy’s shares are trading at Rs 2605.65 on BSE at 1.30 pm.